A 78-year-old man with synchronous diagnosis of prostate cancer and lung adenocarcinoma was referred to our institute for prostate cancer staging with [ 18 F]F-prostate-specific membrane antigen (PSMA) 1007 PET/CT. In addition to the previously known lesion of the right lung, PSMA-targeted PET/CT highlighted 2 areas of abnormal uptake in the brain, in the left frontal and temporal lobes. A subsequent MRI confirmed the lesions observed on PET/CT. Because PSMA-targeting radiopharmaceuticals do not accumulate in healthy brain parenchyma, and recent literature reported promising performances of PSMA-targeted PET/CT in gliomas and metastases from tumors other than prostate cancer, this employment of PSMA radioligands needs to be further explored.
Keyphrases
- pet ct
- prostate cancer
- radical prostatectomy
- cancer therapy
- positron emission tomography
- brain metastases
- magnetic resonance imaging
- white matter
- systematic review
- end stage renal disease
- prognostic factors
- ejection fraction
- high grade
- resting state
- drug delivery
- functional connectivity
- magnetic resonance
- computed tomography
- mental health
- patient reported outcomes
- multiple sclerosis
- cerebral ischemia
- brain injury
- benign prostatic hyperplasia